25.03.2013
- Shire is to buy privately owned U.S. biotech firm SARcode Bioscience, paying $160 million upfront to win rights to a new drug in late-stage development for dry eye diseases. The...
18.10.2012
- U.S. health regulators have approved ThromboGenics's main drug, eye treatment Jetrea, clearing the way for the Belgian biotechnology company to make sustainable profits...
